{
    "abstract": "Background: The quadrivalent meningococcal conjugate vaccine MenACWY-CRM has been shown to be immunogenic and well-tolerated in infants and toddlers. We evaluated antibody persistence for up to 4 years after vaccination with MenACWY-CRM in the first years of life and response to a booster dose administered at 60 months of age. Methods: This was phase 3b, open-label, multicenter extension trial (NCT01148017). We assessed by hSBA and rSBA the persistence of antibody responses to serogroups ACWY in 203 healthy 60-month-olds receiving 4 doses of MenACWY-CRM during infancy (ACWY-4 group), or 2 doses at 12/13 and 15 months or 1 dose at 18 months of age (ACWY-2 group). We administered a MenACWY-CRM dose to 224 primed and 45 na\u00efve 60-month-olds and evaluated safety and antibody response 1 month later. Results: Antibody persistence measured by both assays was higher in primed than na\u00efve 60-month-olds. The percentages of primed children with hSBA titers \u22658 was low for serogroup A (6\u201325%) and moderate for serogroups C (27\u201343%), Y (69\u201374%) and W (56\u201369%). For all serogroups, hSBA antibody geometric mean titers (GMTs) tended to be higher in the ACWY-2 than the ACWY-4 group. Post-booster/single dose, \u226596% of primed and \u226573% of na\u00efve children had hSBA titers \u22658 against each serogroup, and hSBA GMTs were higher in primed children. The booster dose was well-tolerated and no safety concern was identified. We further assessed persistence using rSBA across different age groups and detected no overall correlation between rSBA and hSBA titers. Conclusions: Primary vaccination of infants/toddlers with MenACWY-CRM resulted in moderate antibody persistence against serogroups C, W and Y for up to 4 years after the last priming dose. Regardless of priming schedule, a MenACWY-CRM booster dose at 60 months of age induced a robust immune response against all serogroups and was well-tolerated in all children.",
    "author_highlights": [
        {
            "endOffset": 16672,
            "sentence": "We evaluated 4-year antibody persistence in MenACWY-CRM-primed infants/toddlers.",
            "startOffset": 16592
        },
        {
            "endOffset": 16754,
            "sentence": "hSBA/rSBA titers for all serogroups were higher in primed than in na\u00efve children.",
            "startOffset": 16673
        },
        {
            "endOffset": 16844,
            "sentence": "A 2-dose series in toddlers induced higher persistence than 4 doses given during infancy.",
            "startOffset": 16755
        },
        {
            "endOffset": 16931,
            "sentence": "A booster dose at 60 months of age was immunogenic and well-tolerated in all children.",
            "startOffset": 16845
        },
        {
            "endOffset": 17009,
            "sentence": "We found no correlation between rSBA and hSBA titers in different age groups.",
            "startOffset": 16932
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Bettinger"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Jelfs"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "McIntyre"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Marco A.P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.032",
            "firstpage": "B26",
            "issn": "0264410X",
            "lastpage": "B36",
            "pmid": "22178525",
            "pub_year": 2012,
            "title": "The changing and dynamic epidemiology of meningococcal disease",
            "volume": "30"
        },
        "b0015": {
            "authors": [
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Pace"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.062",
            "firstpage": "B3",
            "issn": "0264410X",
            "lastpage": "B9",
            "pmid": "22607896",
            "pub_year": 2012,
            "title": "Meningococcal disease: Clinical presentation and sequelae",
            "volume": "30"
        },
        "b0020": {
            "authors": [
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Sabatini"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Bosis"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Semino"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Senatore"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Principi"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Esposito"
                }
            ],
            "firstpage": "116",
            "issn": "11212233",
            "lastpage": "119",
            "pmid": "23240173",
            "pub_year": 2012,
            "title": "Clinical presentation of meningococcal disease in childhood",
            "volume": "53"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.03.041",
            "firstpage": "S12",
            "issn": "1054139X",
            "lastpage": "S20",
            "pmid": "27449145",
            "pub_year": 2016,
            "title": "Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements",
            "volume": "59"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Booy"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Gentile"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Nissen"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Whelan"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Abitbol"
                }
            ],
            "doi": "10.1080/21645515.2018.1532248",
            "firstpage": "470",
            "issn": "21645515",
            "lastpage": "480",
            "pmid": "30296197",
            "pub_year": 2019,
            "title": "Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies",
            "volume": "15"
        },
        "b0050": null,
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Anil",
                    "initial": "A.",
                    "last": "Gupta"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Jeanfreau"
                },
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Emmanuel",
                    "initial": "E.",
                    "last": "Walter"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Gill"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.09.092",
            "firstpage": "7865",
            "issn": "0264410X",
            "lastpage": "7872",
            "pmid": "20943209",
            "pub_year": 2010,
            "title": "Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age",
            "volume": "28"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Pellegrini"
                },
                {
                    "first": "Kumaran",
                    "initial": "K.",
                    "last": "Vadivelu-Pechai"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Nissen"
                }
            ],
            "doi": "10.1080/14760584.2018.1521280",
            "firstpage": "865",
            "issn": "14760584",
            "lastpage": "880",
            "pmid": "30198805",
            "pub_year": 2018,
            "title": "An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine",
            "volume": "17"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Stanley L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Jina",
                    "initial": "J.",
                    "last": "Shah"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1128/CVI.00207-09",
            "firstpage": "1810",
            "issn": "15566811",
            "lastpage": "1815",
            "pmid": "19812260",
            "pub_year": 2009,
            "title": "Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra",
            "volume": "16"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "Lopez"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Stamboulian"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.ijid.2014.03.1390",
            "firstpage": "22",
            "issn": "12019712",
            "lastpage": "30",
            "pmid": "24980467",
            "pub_year": 2014,
            "title": "Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers",
            "volume": "26"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Jo Anne",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1080/21645515.2015.1136040",
            "firstpage": "1300",
            "issn": "21645515",
            "lastpage": "1310",
            "pmid": "26829877",
            "pub_year": 2016,
            "title": "Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants",
            "volume": "12"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Johnston"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0b013e31823dce5c",
            "firstpage": "64",
            "issn": "08913668",
            "lastpage": "74",
            "pmid": "22094635",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants",
            "volume": "31"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/CDLI.10.5.780-786.2003",
            "firstpage": "780",
            "issn": "1071412X",
            "lastpage": "786",
            "pmid": "12965904",
            "pub_year": 2003,
            "title": "Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England",
            "volume": "10"
        },
        "b0095": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0100": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1327",
            "firstpage": "1327",
            "issn": "00221007",
            "lastpage": "1348",
            "pmid": "4977281",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. II. Development of natural immunity.",
            "volume": "129"
        },
        "b0105": {
            "authors": [
                {
                    "first": "E. D.G.",
                    "initial": "E.D.G.",
                    "last": "McIntosh"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Br\u00f6ker"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.07.019",
            "firstpage": "4414",
            "issn": "0264410X",
            "lastpage": "4421",
            "pmid": "26187262",
            "pub_year": 2015,
            "title": "Serum bactericidal antibody assays - The role of complement in infection and immunity",
            "volume": "33"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Annette",
                    "initial": "A.",
                    "last": "Karsten"
                },
                {
                    "first": "Jina",
                    "initial": "J.",
                    "last": "Shah"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1086/599117",
            "firstpage": "e1",
            "issn": "10584838",
            "lastpage": "e10",
            "pmid": "19476428",
            "pub_year": 2009,
            "title": "Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents",
            "volume": "49"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Stanley L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Allen",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.jpeds.2014.02.025",
            "firstpage": "1409",
            "issn": "00223476",
            "lastpage": "e4",
            "pmid": "24657122",
            "pub_year": 2014,
            "title": "Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents",
            "volume": "164"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Stanley L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Percell"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1097/INF.0000000000000438",
            "firstpage": "1169",
            "issn": "08913668",
            "lastpage": "1176",
            "pmid": "24911896",
            "pub_year": 2014,
            "title": "Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents",
            "volume": "33"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Shane",
                    "initial": "S.",
                    "last": "Christensen"
                },
                {
                    "first": "Bikash",
                    "initial": "B.",
                    "last": "Verma"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.02.049",
            "firstpage": "2175",
            "issn": "0264410X",
            "lastpage": "2182",
            "pmid": "25744224",
            "pub_year": 2015,
            "title": "Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination",
            "volume": "33"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "Giuseppe L.",
                    "initial": "G.L.",
                    "last": "Ciavarro"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.6.11.12849",
            "firstpage": "881",
            "issn": "15548600",
            "lastpage": "887",
            "pmid": "21339701",
            "pub_year": 2010,
            "title": "Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents",
            "volume": "6"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Robert M.",
                    "initial": "R.M.",
                    "last": "Jacobson"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Jackson"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Allen",
                    "initial": "A.",
                    "last": "Izu"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0b013e318279ac38",
            "firstpage": "e170",
            "issn": "08913668",
            "lastpage": "e177",
            "pmid": "23114372",
            "pub_year": 2013,
            "title": "Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents",
            "volume": "32"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Ameneh",
                    "initial": "A.",
                    "last": "Khatami"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Davis"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Layton"
                },
                {
                    "first": "Tessa",
                    "initial": "T.",
                    "last": "John"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrjlin"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Dobson"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Shelly A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.02.046",
            "firstpage": "2831",
            "issn": "0264410X",
            "lastpage": "2838",
            "pmid": "22394992",
            "pub_year": 2012,
            "title": "Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations",
            "volume": "30"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Charissa",
                    "initial": "C.",
                    "last": "Borja-Tabora"
                },
                {
                    "first": "Cecilia",
                    "initial": "C.",
                    "last": "Montalban"
                },
                {
                    "first": "Ziad A.",
                    "initial": "Z.A.",
                    "last": "Memish"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1186/1471-2334-13-116",
            "issn": "14712334",
            "pmid": "23510357",
            "pub_year": 2013,
            "title": "Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: Results of an open, randomised, controlled study",
            "volume": "13"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Forst\u00e9n"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Boutriau"
                },
                {
                    "first": "V\u00e9ronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van Der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.4161/hv.22166",
            "firstpage": "1892",
            "issn": "21645515",
            "lastpage": "1903",
            "pmid": "23032159",
            "pub_year": 2012,
            "title": "Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers",
            "volume": "8"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Dan M.",
                    "initial": "D.M.",
                    "last": "Granoff"
                },
                {
                    "first": "Jo Anne",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Ram"
                }
            ],
            "doi": "10.1128/IAI.01191-08",
            "firstpage": "764",
            "issn": "00199567",
            "lastpage": "769",
            "pmid": "19047406",
            "pub_year": 2009,
            "title": "Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera",
            "volume": "77"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Kate L.",
                    "initial": "K.L.",
                    "last": "Seib"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Scarselli"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                }
            ],
            "doi": "10.1586/14760584.2015.1016915",
            "firstpage": "841",
            "issn": "14760584",
            "lastpage": "859",
            "pmid": "25704037",
            "pub_year": 2015,
            "title": "Neisseria meningitidis factor H-binding protein fHbp: Key virulence factor and vaccine antigen",
            "volume": "14"
        },
        "b0165": {
            "authors": [
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ram"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "De Tora"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Anemona"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.10.068",
            "firstpage": "29",
            "issn": "0264410X",
            "lastpage": "34",
            "pmid": "22075087",
            "pub_year": 2011,
            "title": "Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source",
            "volume": "30"
        },
        "b0170": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Goldblatt"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1128/IAI.69.3.1568-1573.2001",
            "firstpage": "1568",
            "issn": "00199567",
            "lastpage": "1573",
            "pmid": "11179328",
            "pub_year": 2001,
            "title": "Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection",
            "volume": "69"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Gregory A.",
                    "initial": "G.A.",
                    "last": "Price"
                },
                {
                    "first": "Aimee M.",
                    "initial": "A.M.",
                    "last": "Hollander"
                },
                {
                    "first": "Brian D.",
                    "initial": "B.D.",
                    "last": "Plikaytis"
                },
                {
                    "first": "Brian T.",
                    "initial": "B.T.",
                    "last": "Mocca"
                },
                {
                    "first": "George",
                    "initial": "G.",
                    "last": "Carlone"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Samba O.",
                    "initial": "S.O.",
                    "last": "Sow"
                },
                {
                    "first": "Aldiouma",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Olubukola T.",
                    "initial": "O.T.",
                    "last": "Idoko"
                },
                {
                    "first": "Godwin C.",
                    "initial": "G.C.",
                    "last": "Enwere"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Elie"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Preziosi"
                },
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Margaret C.",
                    "initial": "M.C.",
                    "last": "Bash"
                }
            ],
            "doi": "10.1093/cid/civ504",
            "firstpage": "S554",
            "issn": "10584838",
            "lastpage": "S562",
            "pmid": "26553688",
            "pub_year": 2015,
            "title": "Human complement bactericidal responses to a group a meningococcal conjugate vaccine in africans and comparison to responses measured by 2 other group a immunoassays",
            "volume": "61"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Oumer",
                    "initial": "O.",
                    "last": "Ali"
                },
                {
                    "first": "Abraham",
                    "initial": "A.",
                    "last": "Aseffa"
                },
                {
                    "first": "Ahmed",
                    "initial": "A.",
                    "last": "Bedru"
                },
                {
                    "first": "Tsehaynesh",
                    "initial": "T.",
                    "last": "Lema"
                },
                {
                    "first": "Tesfaye",
                    "initial": "T.",
                    "last": "Moti"
                },
                {
                    "first": "Yenenesh",
                    "initial": "Y.",
                    "last": "Tekletsion"
                },
                {
                    "first": "Alemayehu",
                    "initial": "A.",
                    "last": "Worku"
                },
                {
                    "first": "Haimanot Guebre",
                    "initial": "H.G.",
                    "last": "Xabher"
                },
                {
                    "first": "Lawrence",
                    "initial": "L.",
                    "last": "Yamuah"
                },
                {
                    "first": "Rahamatou Moustapha",
                    "initial": "R.M.",
                    "last": "Boukary"
                },
                {
                    "first": "Jean Marc",
                    "initial": "J.M.",
                    "last": "Collard"
                },
                {
                    "first": "Ibrahim Dan",
                    "initial": "I.D.",
                    "last": "Dano"
                },
                {
                    "first": "Ibrahim",
                    "initial": "I.",
                    "last": "Habiboulaye"
                },
                {
                    "first": "Bassira",
                    "initial": "B.",
                    "last": "Issaka"
                },
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Jusot"
                },
                {
                    "first": "Sani",
                    "initial": "S.",
                    "last": "Ousmane"
                },
                {
                    "first": "Issoufa",
                    "initial": "I.",
                    "last": "Rabe"
                },
                {
                    "first": "Doumagoum Moto",
                    "initial": "D.M.",
                    "last": "Daugla"
                },
                {
                    "first": "Jean Pierre",
                    "initial": "J.P.",
                    "last": "Gami"
                },
                {
                    "first": "Kadidja",
                    "initial": "K.",
                    "last": "Gamougam"
                },
                {
                    "first": "Lodoum",
                    "initial": "L.",
                    "last": "Mbainadji"
                },
                {
                    "first": "Nathan",
                    "initial": "N.",
                    "last": "Naibei"
                },
                {
                    "first": "Maxime",
                    "initial": "M.",
                    "last": "Narb\u00e9"
                },
                {
                    "first": "Jacques",
                    "initial": "J.",
                    "last": "Toralta"
                },
                {
                    "first": "Abdoulaye",
                    "initial": "A.",
                    "last": "Berthe"
                },
                {
                    "first": "Kanny",
                    "initial": "K.",
                    "last": "Diallo"
                },
                {
                    "first": "Mahamadou",
                    "initial": "M.",
                    "last": "Keita"
                },
                {
                    "first": "Uma",
                    "initial": "U.",
                    "last": "Onwuchekwa"
                },
                {
                    "first": "Samba O.",
                    "initial": "S.O.",
                    "last": "Sow"
                },
                {
                    "first": "Boubou",
                    "initial": "B.",
                    "last": "Tamboura"
                },
                {
                    "first": "Awa",
                    "initial": "A.",
                    "last": "Traore"
                },
                {
                    "first": "Alou",
                    "initial": "A.",
                    "last": "Toure"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Clark"
                },
                {
                    "first": "Leonard",
                    "initial": "L.",
                    "last": "Mayer"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Amodu"
                },
                {
                    "first": "Omeiza",
                    "initial": "O.",
                    "last": "Beida"
                },
                {
                    "first": "Galadima",
                    "initial": "G.",
                    "last": "Gadzama"
                },
                {
                    "first": "Babatunji",
                    "initial": "B.",
                    "last": "Omotara"
                },
                {
                    "first": "Zailani",
                    "initial": "Z.",
                    "last": "Sambo"
                },
                {
                    "first": "Shuaibu",
                    "initial": "S.",
                    "last": "Yahya"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Chandramohan"
                },
                {
                    "first": "Brian M.",
                    "initial": "B.M.",
                    "last": "Greenwood"
                },
                {
                    "first": "Musa",
                    "initial": "M.",
                    "last": "Hassan-King"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Manigart"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Nascimento"
                },
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Stuart"
                },
                {
                    "first": "Arouna",
                    "initial": "A.",
                    "last": "Woukeu"
                },
                {
                    "first": "Nicole E.",
                    "initial": "N.E.",
                    "last": "Basta"
                },
                {
                    "first": "Xilian",
                    "initial": "X.",
                    "last": "Bai"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Findlow"
                },
                {
                    "first": "Serge",
                    "initial": "S.",
                    "last": "Alavo"
                },
                {
                    "first": "Hubert",
                    "initial": "H.",
                    "last": "Bassene"
                },
                {
                    "first": "Aldiouma",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Marietou",
                    "initial": "M.",
                    "last": "Dieng"
                },
                {
                    "first": "Souleymane",
                    "initial": "S.",
                    "last": "Doucour\u00e9"
                },
                {
                    "first": "Jules Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Gomis"
                },
                {
                    "first": "Assane",
                    "initial": "A.",
                    "last": "Ndiaye"
                },
                {
                    "first": "Cheikh",
                    "initial": "C.",
                    "last": "Sokhna"
                },
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Trape"
                },
                {
                    "first": "Bugri",
                    "initial": "B.",
                    "last": "Akalifa"
                },
                {
                    "first": "Abudulai",
                    "initial": "A.",
                    "last": "Forgor"
                },
                {
                    "first": "Abraham",
                    "initial": "A.",
                    "last": "Hodgson"
                },
                {
                    "first": "Isaac",
                    "initial": "I.",
                    "last": "Osei"
                },
                {
                    "first": "Stephen L.",
                    "initial": "S.L.",
                    "last": "Quaye"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Williams"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Wontuo"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Irving"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Bennett"
                },
                {
                    "first": "Dorothea",
                    "initial": "D.",
                    "last": "Hill"
                },
                {
                    "first": "Odile",
                    "initial": "O.",
                    "last": "Harrison"
                },
                {
                    "first": "Martin C.",
                    "initial": "M.C.",
                    "last": "Maiden"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Rebbetts"
                },
                {
                    "first": "Eleanor",
                    "initial": "E.",
                    "last": "Watkins"
                }
            ],
            "doi": "10.1093/infdis/jiv211",
            "firstpage": "1298",
            "issn": "00221899",
            "lastpage": "1307",
            "pmid": "25858956",
            "pub_year": 2015,
            "title": "The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group a meningococcal conjugate vaccine",
            "volume": "212"
        },
        "b0185": {
            "authors": [
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Kristiansen"
                },
                {
                    "first": "Absatou Ky",
                    "initial": "A.K.",
                    "last": "Ba"
                },
                {
                    "first": "Abdoul Salam",
                    "initial": "A.S.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Idrissa",
                    "initial": "I.",
                    "last": "Sanou"
                },
                {
                    "first": "Rasmata",
                    "initial": "R.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Lassana",
                    "initial": "L.",
                    "last": "Sangar\u00e9"
                },
                {
                    "first": "Fabien",
                    "initial": "F.",
                    "last": "Diomand\u00e9"
                },
                {
                    "first": "Denis",
                    "initial": "D.",
                    "last": "Kandolo"
                },
                {
                    "first": "Inger Marie",
                    "initial": "I.M.",
                    "last": "Saga"
                },
                {
                    "first": "Lara",
                    "initial": "L.",
                    "last": "Misegades"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Pr\u00e9ziosi"
                },
                {
                    "first": "Dominique A.",
                    "initial": "D.A.",
                    "last": "Caugant"
                }
            ],
            "doi": "10.1186/s12879-014-0663-4",
            "issn": "14712334",
            "pmid": "25472422",
            "pub_year": 2014,
            "title": "Persistent low carriage of serogroup A two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac",
            "volume": "14"
        },
        "b0190": {
            "authors": [
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Kristiansen"
                },
                {
                    "first": "Fabien",
                    "initial": "F.",
                    "last": "Diomand\u00e9"
                },
                {
                    "first": "Absatou Ky",
                    "initial": "A.K.",
                    "last": "Ba"
                },
                {
                    "first": "Idrissa",
                    "initial": "I.",
                    "last": "Sanou"
                },
                {
                    "first": "Abdoul Salam",
                    "initial": "A.S.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Rasmata",
                    "initial": "R.",
                    "last": "Ou\u00e9draogo"
                },
                {
                    "first": "Lassana",
                    "initial": "L.",
                    "last": "Sangar\u00e9"
                },
                {
                    "first": "Denis",
                    "initial": "D.",
                    "last": "Kandolo"
                },
                {
                    "first": "Flavien",
                    "initial": "F.",
                    "last": "Ak\u00e9"
                },
                {
                    "first": "Inger Marie",
                    "initial": "I.M.",
                    "last": "Saga"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Lara",
                    "initial": "L.",
                    "last": "Misegades"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                },
                {
                    "first": "Jennifer Dolan",
                    "initial": "J.D.",
                    "last": "Thomas"
                },
                {
                    "first": "Sylvestre R.",
                    "initial": "S.R.",
                    "last": "Tiendrebeogo"
                },
                {
                    "first": "Musa",
                    "initial": "M.",
                    "last": "Hassan-King"
                },
                {
                    "first": "Mamoudou H.",
                    "initial": "M.H.",
                    "last": "Djingarey"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Pr\u00e9ziosi"
                },
                {
                    "first": "F. Marc",
                    "initial": "F.M.",
                    "last": "Laforce"
                },
                {
                    "first": "Dominique A.",
                    "initial": "D.A.",
                    "last": "Caugant"
                }
            ],
            "doi": "10.1093/cid/cis892",
            "firstpage": "354",
            "issn": "10584838",
            "lastpage": "363",
            "pmid": "23087396",
            "pub_year": 2013,
            "title": "Impact of the serogroup a meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity",
            "volume": "56"
        }
    },
    "body_text": [
        {
            "endOffset": 33343,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The subsets of children with rSBA assessments in each of the 3 studies included in the exploratory analyses had comparable demographic characteristics at each timepoint (Table S1).",
            "startOffset": 33163,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 37733,
            "parents": [],
            "secId": "s0065",
            "sentence": "We also observed a more rapid decline of hSBA, but not rSBA, antibody levels against serogroup A compared with the other serogroups, over 4 years after priming.",
            "startOffset": 37573,
            "title": "Discussion"
        },
        {
            "endOffset": 31912,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Less than 3% of primed and 6% of na\u00efve children reported rash or fever, and none of the AEs were severe (Table 4).",
            "startOffset": 31798,
            "title": "Safety"
        },
        {
            "endOffset": 25966,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "We collected serious AEs (SAEs) throughout the study.",
            "startOffset": 25913,
            "title": "Safety assessments"
        },
        {
            "endOffset": 24116,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For each site, an Institutional Review Board reviewed and approved the study protocol, amendments and informed consent forms.",
            "startOffset": 23991,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26953,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We randomly selected subsets for rSBA assessments from groups ACWY-4 (N = 50), ACWY-2 (N = 75), Na\u00efve-40M (N = 50) and Na\u00efve-60M (N = 45).",
            "startOffset": 26815,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28385,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The ATP cohorts for persistence included 210 in group ACWY-4, 119 in group ACWY-2 and 51 children in group Na\u00efve-40M (Fig. 2).",
            "startOffset": 28259,
            "title": "Demographics"
        },
        {
            "endOffset": 29701,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "By 60 months of age, the percentages of primed children with hSBA titers \u22658 were lower, but remained higher than in na\u00efve children for serogroups W and Y (with non-overlapping 95% CIs) (Table 2).",
            "startOffset": 29506,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31530,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Pain was the most frequent solicited local reaction, reported in 40\u201342% of children in groups ACWY-4 and ACWY-2, and 49% of children in group Na\u00efve-60M (Table 4), with no reports of severe pain across groups.",
            "startOffset": 31322,
            "title": "Safety"
        },
        {
            "endOffset": 27066,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We included all exposed children with solicited/unsolicited safety data at each timepoint in the safety analyses.",
            "startOffset": 26953,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 27802,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We performed ad hoc analyses for rSBA assessments in the subsets of previously vaccinated participants (i.e., not including na\u00efve children).",
            "startOffset": 27662,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28761,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The ATP cohorts for persistence at this timepoint included 203 primed (123 and 80 in groups ACWY-4 and ACWY-2, respectively) and 45 na\u00efve children (Fig. 2).",
            "startOffset": 28605,
            "title": "Demographics"
        },
        {
            "endOffset": 32914,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "We recorded no SAEs and no deaths throughout the study.",
            "startOffset": 32859,
            "title": "Safety"
        },
        {
            "endOffset": 21030,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, data on the persistence of bactericidal antibodies following infants and toddlers priming with 1 MenACWY-CRM dose are still scarce.",
            "startOffset": 20890,
            "title": "Introduction"
        },
        {
            "endOffset": 26124,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "For all participants enrolled at 40 months of age, investigators collected SAEs at least possibly related to study procedures within 24 h from the blood draw.",
            "startOffset": 25966,
            "title": "Safety assessments"
        },
        {
            "endOffset": 26442,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We planned to enroll 200 children in each of the ACWY-4 and ACWY-2 groups.",
            "startOffset": 26368,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 20162,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 20161,
                    "startOffset": 20158
                }
            },
            "secId": "s0005",
            "sentence": "More recently, an upsurge of serogroup W-caused IMD has been observed in South America, Europe, Australia and regions of sub-Saharan Africa [9].",
            "startOffset": 20018,
            "title": "Introduction"
        },
        {
            "endOffset": 38938,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 38937,
                    "startOffset": 38933
                }
            },
            "secId": "s0065",
            "sentence": "We did not evaluate how rapidly the anamnestic response could occur at this age, however a previous study found that 98\u2013100% of adolescents receiving a booster dose 5 years after primary vaccination with MenACWY-CRM had hSBA titers \u22658 by 7 days post-vaccination [27].",
            "startOffset": 38671,
            "title": "Discussion"
        },
        {
            "endOffset": 36437,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 36436,
                    "startOffset": 36432
                }
            },
            "secId": "s0065",
            "sentence": "This finding might be explained by the difference in maturity of the immune system between toddlers and infants [16].",
            "startOffset": 36320,
            "title": "Discussion"
        },
        {
            "endOffset": 24174,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at http://www.clinicaltrials.gov.",
            "startOffset": 24117,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30388,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Similar trends were observed for percentages of children with hSBA titers \u22654 at all timepoints (Table 2).",
            "startOffset": 30283,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31001,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-booster/single dose vaccination, \u226593% of children achieved rSBA titers \u22658 against each serogroup (Table 3).",
            "startOffset": 30889,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35703,
            "parents": [],
            "secId": "s0065",
            "sentence": "This is the first study to assess long-term persistence of functional antibodies after a multi-dose regimen of MenACWY-CRM in infants and toddlers, using both rSBA and hSBA.",
            "startOffset": 35530,
            "title": "Discussion"
        },
        {
            "endOffset": 37572,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, the percentages of children with hSBA titers \u22654 compared with those with rSBA titers \u22658 were higher for serogroups C and W in the current study, regardless of the number of MenACWY-CRM doses received.",
            "startOffset": 37363,
            "title": "Discussion"
        },
        {
            "endOffset": 29233,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 40 months of age, the percentages of children with hSBA titers \u22658 and antibody hSBA GMTs were higher in groups ACWY-2 and ACWY-4 than in group Na\u00efve-40M for serogroups C, W and Y (Table 2).",
            "startOffset": 29041,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31193,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall, 14\u201342% of primed 60-month-olds reported solicited local reactions, compared with 20\u201349% in the na\u00efve cohort.",
            "startOffset": 31076,
            "title": "Safety"
        },
        {
            "endOffset": 20889,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 20756,
                    "startOffset": 20749
                },
                "b0065": {
                    "endOffset": 20756,
                    "startOffset": 20749
                },
                "b0070": {
                    "endOffset": 20756,
                    "startOffset": 20749
                },
                "b0075": {
                    "endOffset": 20756,
                    "startOffset": 20749
                },
                "b0080": {
                    "endOffset": 20888,
                    "startOffset": 20884
                }
            },
            "secId": "s0005",
            "sentence": "The vaccine is immunogenic with an acceptable safety profile [12\u201315], and a dose administered up to 5 years post-primary vaccination induces a robust booster response in individuals aged >2 years [16].",
            "startOffset": 20688,
            "title": "Introduction"
        },
        {
            "endOffset": 33941,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The percentages of individuals with rSBA titers \u22658 and antibody GMTs were higher in groups previously vaccinated with MenACWY-CRM than in the corresponding na\u00efve cohorts, for all age categories and serogroups (including A), except for serogroup C for children 7\u201310 years of age receiving either 1 or 2 doses of MenACWY-CRM 5 years earlier (Table S2).",
            "startOffset": 33591,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 23735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We also offered a dose to children from the group Na\u00efve-40M.",
            "startOffset": 23675,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32228,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In 4% of children in ACWY-4, 6% in ACWY-2, and 6% in Na\u00efve-60M groups, investigators considered the AEs as related to vaccination, with most being injection-site reactions.",
            "startOffset": 32056,
            "title": "Safety"
        },
        {
            "endOffset": 36837,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 36749,
                    "startOffset": 36746
                }
            },
            "secId": "s0065",
            "sentence": "Nevertheless, as IMD incidence is the highest in infancy and peaks again in adolescence [5], these age groups remain the main target for vaccination against meningococcal disease.",
            "startOffset": 36658,
            "title": "Discussion"
        },
        {
            "endOffset": 43711,
            "parents": [],
            "secId": "s0080",
            "sentence": "GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 43573,
            "title": "Funding"
        },
        {
            "endOffset": 25748,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Parents/legally accepted representatives recorded any solicited AE occurring within 7 days post-vaccination on diary cards.",
            "startOffset": 25625,
            "title": "Safety assessments"
        },
        {
            "endOffset": 40703,
            "parents": [],
            "secId": "s0065",
            "sentence": "Generally, immune responses against serogroups C, W and Y tend to be similar whether measured by hSBA or rSBA, although rSBA GMTs run several-fold higher than hSBA GMTs.",
            "startOffset": 40534,
            "title": "Discussion"
        },
        {
            "endOffset": 22772,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2019.06.076.",
            "startOffset": 22638,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33590,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 33499,
                    "startOffset": 33495
                }
            },
            "secId": "s0060",
            "sentence": "Antibody persistence at 5 years post-vaccination with MenACWY-CRM as assessed by hSBA in children aged 2\u201310 years [23] and adolescents aged 11\u201318 years [23] at first vaccination has been previously reported; rSBA results are presented in Table S2.",
            "startOffset": 33343,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 43182,
            "parents": [],
            "secId": "s0070",
            "sentence": "A booster dose of MenACWY-CRM in 60-month-olds elicited a strong anamnestic response 1 month after vaccination and did not raise any safety concerns.",
            "startOffset": 43033,
            "title": "Conclusions"
        },
        {
            "endOffset": 25107,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "We evaluated antibody levels using hSBA (GSK Clinical Laboratory Sciences, Marburg, Germany) or rSBA (Public Health England, United Kingdom).",
            "startOffset": 24966,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 27661,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 27470,
                    "startOffset": 27466
                },
                "b0110": {
                    "endOffset": 27491,
                    "startOffset": 27487
                }
            },
            "secId": "s0035",
            "sentence": "Briefly, they assessed antibody persistence in healthy individuals aged 2\u201310 years [12] and 11\u201318-years [22] at first vaccination with MenACWY-CRM according to a single- or 2-dose (in the 2\u201310 years group only) schedule, as compared with MenACWY-na\u00efve aged-matched participants.",
            "startOffset": 27383,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43572,
            "parents": [],
            "secId": "s0080",
            "sentence": "The study was sponsored by the Novartis Vaccines Division; on 2 March 2015 Novartis\u2019 non-influenza Vaccines Business was acquired by the GlaxoSmithKline group of companies.",
            "startOffset": 43400,
            "title": "Funding"
        },
        {
            "endOffset": 20017,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 20016,
                    "startOffset": 20011
                },
                "b0030": {
                    "endOffset": 20016,
                    "startOffset": 20011
                },
                "b0035": {
                    "endOffset": 20016,
                    "startOffset": 20011
                },
                "b0040": {
                    "endOffset": 20016,
                    "startOffset": 20011
                }
            },
            "secId": "s0005",
            "sentence": "Six Neisseria meningitidis serogroups cause most IMD cases, with serogroups B, C and Y predominating in the Americas and Europe, serogroups A and C in Asia, and serogroups B, C, X, and W in Africa [5\u20138].",
            "startOffset": 19814,
            "title": "Introduction"
        },
        {
            "endOffset": 34773,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At 40 and 60 months of age across all groups, the percentages with hSBA titers \u22654 were lower than for rSBA titers \u22658 for serogroup A, tended to be higher for serogroups C and W and tended to be lower for serogroup Y, (Tables 2 and 3).",
            "startOffset": 34539,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 39575,
            "parents": [],
            "secId": "s0065",
            "sentence": "When assessing the evolution of hSBA and rSBA titers over time in the same individual, we could not establish any correlation between the assays for any of the serogroups regardless of age at priming, number of primary doses or interval since priming.",
            "startOffset": 39324,
            "title": "Discussion"
        },
        {
            "endOffset": 43393,
            "parents": [],
            "secId": "s0075",
            "sentence": "Menveo is a trademark owned by the GSK group of companies.",
            "startOffset": 43335,
            "title": "Trademark statement"
        },
        {
            "endOffset": 22577,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 22576,
                    "startOffset": 22572
                }
            },
            "secId": "s0015",
            "sentence": "We administered one 0.5 mL dose of MenACWY-CRM to all vaccine-primed and vaccine-na\u00efve children enrolled at age 60 months by intramuscular injection in the left deltoid, as previously described [11].",
            "startOffset": 22378,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31797,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The incidence of solicited general reactions was comparable between groups, with irritability being the most frequently reported in 17\u201319% of children in groups ACWY-4 and ACWY-2, and 16% in group Na\u00efve-60M.",
            "startOffset": 31590,
            "title": "Safety"
        },
        {
            "endOffset": 30744,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 60 months of age, the percentages of children with rSBA titers \u22658 and rSBA GMTs were higher in the ACWY-2 group for all serogroups except serogroup C than in the ACWY-4 and Na\u00efve groups.",
            "startOffset": 30555,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22638,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We also offered a dose to children from the group Na\u00efve-40M.",
            "startOffset": 22578,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27972,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We assessed correlation between rSBA and hSBA titers against each serogroup by calculating the Pearson correlation coefficient and its p-value, overall and by timepoint.",
            "startOffset": 27803,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35029,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Although a few combinations of serogroup, age, timepoint of vaccination and number of doses had a statistically significant correlation coefficient between rSBA and hSBA titers, we could not identify an overall correlation between the 2 assays (Table S3).",
            "startOffset": 34774,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 22291,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We enrolled age-matched MenACWY vaccine-na\u00efve children (groups Na\u00efve-40M and Na\u00efve-60M) as controls for immunogenicity analyses (Fig. 2).",
            "startOffset": 22154,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39324,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 39323,
                    "startOffset": 39319
                }
            },
            "secId": "s0065",
            "sentence": "In the current study, the safety profile was similar to that reported for 2\u20135-year-olds receiving 1 dose of MenACWY-CRM [12].",
            "startOffset": 39199,
            "title": "Discussion"
        },
        {
            "endOffset": 38241,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 38240,
                    "startOffset": 38236
                }
            },
            "secId": "s0065",
            "sentence": "N. meningitidis strains express the factor H binding protein, which is able to selectively bind the key negative regulator of the alternative complement pathway (human factor H), and enables the pathogen to evade alternative complement-mediated killing by the host innate immune system and to survive in human serum and blood [31].",
            "startOffset": 37910,
            "title": "Discussion"
        },
        {
            "endOffset": 31589,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Erythema was the most frequently reported severe reaction.",
            "startOffset": 31531,
            "title": "Safety"
        },
        {
            "endOffset": 25423,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "We also evaluated the percentage of individuals with titers against each serogroup \u22654 for hSBA and \u2265128 for rSBA.",
            "startOffset": 25310,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 28129,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "We performed all analyses using SAS version 9.3.",
            "startOffset": 28081,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The null hypothesis was that the true correlation coefficient [\u03c1] is equal to 0 (indicating no correlation).",
            "startOffset": 27973,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31321,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Most reactions were mild to moderate, with severe reactions occurring in <7% of primed children and <14% in na\u00efve participants.",
            "startOffset": 31194,
            "title": "Safety"
        },
        {
            "endOffset": 29506,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "We observed a trend for higher antibody persistence against all serogroups in group ACWY-2 compared with ACWY-4 (Table 2).",
            "startOffset": 29384,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 20360,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 20359,
                    "startOffset": 20352
                },
                "b0055": {
                    "endOffset": 20359,
                    "startOffset": 20352
                }
            },
            "secId": "s0005",
            "sentence": "The CRM197-conjugate vaccine MenACWY-CRM (Menveo, GSK) is licensed for use against meningococcal disease in individuals from 2 months of age in several countries, and from 2 years in Europe [10,11].",
            "startOffset": 20162,
            "title": "Introduction"
        },
        {
            "endOffset": 43032,
            "parents": [],
            "secId": "s0070",
            "sentence": "While hSBA antibody levels against serogroup A declined over time, high rSBA GMTs were maintained for up to 4 years post-primary vaccination.",
            "startOffset": 42891,
            "title": "Conclusions"
        },
        {
            "endOffset": 38390,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 38389,
                    "startOffset": 38385
                }
            },
            "secId": "s0065",
            "sentence": "Factor H is not present in baby rabbit complement, which impacts the complement-mediated killing of N. meningitidis and leads to higher titers [32].",
            "startOffset": 38242,
            "title": "Discussion"
        },
        {
            "endOffset": 36319,
            "parents": [],
            "secId": "s0065",
            "sentence": "We also found that for all meningococcal serogroups, antibody levels in 60-month-old children were higher following immunization as toddlers with a 1- or 2-dose series compared with a 4-dose series during infancy, although similar percentages of children had protective titers regardless of the age at primary vaccination.",
            "startOffset": 35997,
            "title": "Discussion"
        },
        {
            "endOffset": 20687,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 20686,
                    "startOffset": 20682
                }
            },
            "secId": "s0005",
            "sentence": "In the United States (US), MenACWY-CRM is licensed as a 4-dose infant series (at 2, 4, 6 and 12 months of age), a 2-dose series (administered \u22653 months apart) in 7\u201323-month-olds, and as a single dose for individuals 2\u201355 years old, with an additional dose to be administered in 2\u20135 year-olds at continued risk of disease [11].",
            "startOffset": 20361,
            "title": "Introduction"
        },
        {
            "endOffset": 24833,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "We assessed the safety and tolerability of the MenACWY-CRM booster/single dose administered at 60 months of age.",
            "startOffset": 24721,
            "title": "Study objectives"
        },
        {
            "endOffset": 28604,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Of these subjects, 270 children continued in the study at the second assessment timepoint at 60 months of age (136 in group ACWY-4, 89 in group ACWY-2 and 45 na\u00efve participants), of whom 269 received a MenACWY-CRM dose.",
            "startOffset": 28385,
            "title": "Demographics"
        },
        {
            "endOffset": 32055,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Post-vaccination at age 60 months, parents reported any unsolicited AEs in 7% of children in ACWY-4, 8% in ACWY-2, and 12% in Na\u00efve-60M groups.",
            "startOffset": 31912,
            "title": "Safety"
        },
        {
            "endOffset": 27382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In order to include different age groups, the same analyses were conducted for 2 other studies which we previously reported the design and hSBA results in detail.",
            "startOffset": 27220,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42733,
            "parents": [],
            "secId": "s0065",
            "sentence": "Finally, in addition to the difference in source complement, the two assays were performed in different laboratories with each following its own protocol and strain selection procedure.",
            "startOffset": 42548,
            "title": "Discussion"
        },
        {
            "endOffset": 23474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Text S1 (Supplementary Material) gives the full list of enrolment exclusion criteria.",
            "startOffset": 23389,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32380,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "We collected medically-attended AEs for 8% of children in ACWY-4, 13% in ACWY-2 and 10% in Na\u00efve-60M groups; none were related to vaccination (Table 4).",
            "startOffset": 32228,
            "title": "Safety"
        },
        {
            "endOffset": 37362,
            "parents": [],
            "secId": "s0065",
            "sentence": "Consistent with these studies, at 4 years post-last primary dose, we observed that the percentages of children with hSBA titers \u22654 were considerably lower than those with rSBA titers \u22658 for serogroup A and that antibody hSBA GMTs were lower than those measured by rSBA for all serogroups.",
            "startOffset": 37074,
            "title": "Discussion"
        },
        {
            "endOffset": 41107,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 41106,
                    "startOffset": 41102
                }
            },
            "secId": "s0065",
            "sentence": "Data from a mass-vaccination campaign with a monovalent serogroup A conjugate vaccine in African countries also showed this divergence between waning hSBA and relatively-constant rSBA antibody levels over 1-year post-immunization [35].",
            "startOffset": 40872,
            "title": "Discussion"
        },
        {
            "endOffset": 30283,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody GMTs against serogroups A and C were higher in group ACWY-2 than in ACWY-4 (Table 2).",
            "startOffset": 30189,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26814,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In the ATP cohort, we performed hSBA analyses for persistence at 40 and 60 months of age and for immunogenicity at 1 month post-vaccination.",
            "startOffset": 26674,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21322,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we present new data on the persistence of antibody titers in MenACWY-CRM-vaccinated children at ages 40 and 60 months.",
            "startOffset": 21198,
            "title": "Introduction"
        },
        {
            "endOffset": 23674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 23673,
                    "startOffset": 23669
                }
            },
            "secId": "s0015",
            "sentence": "We administered one 0.5 mL dose of MenACWY-CRM to all vaccine-primed and vaccine-na\u00efve children enrolled at age 60 months by intramuscular injection in the left deltoid, as previously described [11].",
            "startOffset": 23475,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24720,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Post-hoc exploratory analyses assessed immunogenicity endpoints using rSBA.",
            "startOffset": 24645,
            "title": "Study objectives"
        },
        {
            "endOffset": 27219,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "In addition, we conducted exploratory analyses assessing the persistence of antibody levels up to 5 years following initial vaccination with MenACWY-CRM.",
            "startOffset": 27066,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39737,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 39736,
                    "startOffset": 39732
                }
            },
            "secId": "s0065",
            "sentence": "Similar results were seen in a previous study in adolescents who received a single dose of either MenACWY-CRM or a quadrivalent ACWY polysaccharide vaccine [33].",
            "startOffset": 39576,
            "title": "Discussion"
        },
        {
            "endOffset": 39198,
            "parents": [],
            "secId": "s0065",
            "sentence": "We observed no differences between the incidence of AEs in primed children, regardless of having previously received a 1-, 2- or 4-dose primary vaccination series.",
            "startOffset": 39035,
            "title": "Discussion"
        },
        {
            "endOffset": 23388,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We enrolled age-matched MenACWY vaccine-na\u00efve children (groups Na\u00efve-40M and Na\u00efve-60M) as controls for immunogenicity analyses (Fig. 2).",
            "startOffset": 23251,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29962,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody persistence tended to be higher in group ACWY-2 than in ACWY-4 for each serogroup (Table 2).",
            "startOffset": 29861,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30188,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody GMTs against all serogroups were higher in primed children than in group Na\u00efve-60M.",
            "startOffset": 30096,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32859,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Only 1 AE (arthralgia) was moderate in severity, while the other 4 were mild.",
            "startOffset": 32782,
            "title": "Safety"
        },
        {
            "endOffset": 42547,
            "parents": [],
            "secId": "s0065",
            "sentence": "Further, our comparisons of hSBA with rSBA assessments for antibody persistence were limited by the relatively small number of participants who had both rSBA and hSBA titers assessed, as well as the different number of previously administered doses within the same age category.",
            "startOffset": 42269,
            "title": "Discussion"
        },
        {
            "endOffset": 42121,
            "parents": [],
            "secId": "s0065",
            "sentence": "In the primed groups, we enrolled only children who had previously been vaccinated in the parent study whose parents/legally accepted representatives were willing to participate in the extension trial; therefore, randomization was not possible and this led to a slight imbalance between groups in the participants\u2019 baseline characteristics.",
            "startOffset": 41781,
            "title": "Discussion"
        },
        {
            "endOffset": 31067,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "We observed similar trends for rSBA titers \u2265128 (data not shown).",
            "startOffset": 31002,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 39034,
            "parents": [],
            "secId": "s0065",
            "sentence": "Among 60-month-olds, a dose of MenACWY-CRM was well tolerated in both primed and na\u00efve children.",
            "startOffset": 38938,
            "title": "Discussion"
        },
        {
            "endOffset": 22377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Text S1 (Supplementary Material) gives the full list of enrolment exclusion criteria.",
            "startOffset": 22292,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35263,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At 40 and 60 months of age across all groups, the percentages with hSBA titers \u22654 were lower than for rSBA titers \u22658 for serogroup A, tended to be higher for serogroups C and W and tended to be lower for serogroup Y, (Tables 2 and 3).",
            "startOffset": 35029,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 41693,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 41548,
                    "startOffset": 41544
                }
            },
            "secId": "s0065",
            "sentence": "The immunogenicity results obtained in our study complement those obtained in other persistence trials [16], providing evidence that hSBA antibodies persist for up to 4 years post-MenACWY-CRM vaccination in all age categories for which it is indicated.",
            "startOffset": 41441,
            "title": "Discussion"
        },
        {
            "endOffset": 42268,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 42215,
                    "startOffset": 42211
                }
            },
            "secId": "s0065",
            "sentence": "While our immunogenicity results are in agreement with those of other persistence trials [16], we did not perform any formal statistical analyses.",
            "startOffset": 42122,
            "title": "Discussion"
        },
        {
            "endOffset": 41441,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 41325,
                    "startOffset": 41318
                },
                "b0185": {
                    "endOffset": 41325,
                    "startOffset": 41318
                },
                "b0190": {
                    "endOffset": 41325,
                    "startOffset": 41318
                }
            },
            "secId": "s0065",
            "sentence": "Nevertheless, there were no cases of serogroup A disease, and nasopharyngeal carriage remained low in both vaccinated and unvaccinated populations 2 years after campaign implementation, despite low hSBA levels [36\u201338], raising the question of whether rSBA titers could also be used to evaluate the persistence of the immune response.",
            "startOffset": 41108,
            "title": "Discussion"
        },
        {
            "endOffset": 25309,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 25308,
                    "startOffset": 25301
                },
                "b0095": {
                    "endOffset": 25308,
                    "startOffset": 25301
                },
                "b0100": {
                    "endOffset": 25308,
                    "startOffset": 25301
                },
                "b0105": {
                    "endOffset": 25308,
                    "startOffset": 25301
                }
            },
            "secId": "s0025",
            "sentence": "We assessed immune responses to MenACWY-CRM as the percentage of individuals with reciprocal hSBA/rSBA titers \u22658 against each serogroup and geometric mean titers (GMTs), as previously described [18\u201321].",
            "startOffset": 25107,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 40027,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 40026,
                    "startOffset": 40022
                },
                "b0095": {
                    "endOffset": 39829,
                    "startOffset": 39825
                }
            },
            "secId": "s0065",
            "sentence": "An hSBA titer \u22654 is considered the accepted correlate of protection against serogroup C [19], a value which has been extrapolated to all other meningococcal serogroups, while rSBA titers \u22658 correlate with serogroup C vaccine efficacy estimates from post-licensure surveillance studies [18].",
            "startOffset": 39737,
            "title": "Discussion"
        },
        {
            "endOffset": 37909,
            "parents": [],
            "secId": "s0065",
            "sentence": "The more pronounced difference between assays for serogroup A is not readily explained but might suggest that serogroup A bacteria are more dependent on factor H for survival.",
            "startOffset": 37734,
            "title": "Discussion"
        },
        {
            "endOffset": 29024,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Overall, the groups were relatively balanced in terms of baseline characteristics, although the na\u00efve groups at both timepoints included more female participants compared with the primed groups and there was a slight imbalance in terms of ethnic origin (Table 1).",
            "startOffset": 28761,
            "title": "Demographics"
        },
        {
            "endOffset": 21197,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 21196,
                    "startOffset": 21189
                },
                "b0085": {
                    "endOffset": 21196,
                    "startOffset": 21189
                }
            },
            "secId": "s0005",
            "sentence": "We have previously shown that MenACWY-CRM was highly immunogenic and well tolerated in healthy infants and toddlers when co-administered with routine vaccines [15,17].",
            "startOffset": 21030,
            "title": "Introduction"
        },
        {
            "endOffset": 30095,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post-booster/single-dose vaccination, \u226596% of primed and \u226573% of na\u00efve children had hSBA titers \u22658 against each serogroup.",
            "startOffset": 29962,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38498,
            "parents": [],
            "secId": "s0065",
            "sentence": "We demonstrated that a booster dose of MenACWY-CRM at 60 months of age induced a robust anamnestic response.",
            "startOffset": 38390,
            "title": "Discussion"
        },
        {
            "endOffset": 40533,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 40532,
                    "startOffset": 40528
                }
            },
            "secId": "s0065",
            "sentence": "The decline in hSBA titers over time is known to be age- and serogroup-dependent [16].",
            "startOffset": 40447,
            "title": "Discussion"
        },
        {
            "endOffset": 32533,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Among children in all 3 groups, there were no SAEs considered at least possibly related to study procedures following the blood draw at 40 months of age.",
            "startOffset": 32380,
            "title": "Safety"
        },
        {
            "endOffset": 34188,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 34097,
                    "startOffset": 34093
                }
            },
            "secId": "s0060",
            "sentence": "Antibody persistence at 5 years post-vaccination with MenACWY-CRM as assessed by hSBA in children aged 2\u201310 years [23] and adolescents aged 11\u201318 years [23] at first vaccination has been previously reported; rSBA results are presented in Table S1.",
            "startOffset": 33941,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 23850,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We conducted the study in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 23735,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23990,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "We obtained written informed consent from the study participants or their parents/legally accepted representatives before study enrollment.",
            "startOffset": 23851,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28258,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "We enrolled 388 children 40 months of age: 214 in group ACWY-4, 121 in group ACWY-2 and 53 na\u00efve children.",
            "startOffset": 28152,
            "title": "Demographics"
        },
        {
            "endOffset": 29860,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Among primed children, the percentages with hSBA titers \u22658 were low for serogroup A (6\u201325%) and moderate for serogroups C (27\u201343%), Y (69\u201374%) and W (56\u201369%).",
            "startOffset": 29702,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37073,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 36979,
                    "startOffset": 36966
                },
                "b0125": {
                    "endOffset": 36979,
                    "startOffset": 36966
                },
                "b0135": {
                    "endOffset": 36979,
                    "startOffset": 36966
                },
                "b0140": {
                    "endOffset": 36979,
                    "startOffset": 36966
                },
                "b0145": {
                    "endOffset": 37001,
                    "startOffset": 36994
                },
                "b0150": {
                    "endOffset": 37001,
                    "startOffset": 36994
                }
            },
            "secId": "s0065",
            "sentence": "The hSBA and rSBA antibody titers in our study were comparable to those in prior trials assessing the persistence of MenACWY-CRM [16,25,27,28] or MenACWY-TT [29,30] after vaccination of infants and toddlers, as well as other age groups.",
            "startOffset": 36837,
            "title": "Discussion"
        },
        {
            "endOffset": 22153,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 22152,
                    "startOffset": 22148
                }
            },
            "secId": "s0015",
            "sentence": "We evaluated the persistence of antibody titers in 2 groups of healthy 40- and 60-month-olds previously vaccinated with MenACWY-CRM, primed either according to a 3 + 1 schedule at 2, 4, 6, and 12/13 months of age (group ACWY-4) or according to a 2-dose (at 12/13 months and 15 months of age) or single-dose schedule (at 18 months of age) (group ACWY-2) [17].",
            "startOffset": 21795,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24966,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "We collected blood samples (10 mL) at 40 and 60 months of age, and at 1 month post-vaccination (Fig. 2).",
            "startOffset": 24862,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 40447,
            "parents": [],
            "secId": "s0065",
            "sentence": "Thus, even in the absence of a clear correlation between the two assays, there is evidence that both hSBA and rSBA can be used to monitor response to vaccination and persistence of immune response in individuals of all ages.",
            "startOffset": 40223,
            "title": "Discussion"
        },
        {
            "endOffset": 25912,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Investigators also recorded unsolicited AEs from day (D) 1 to D7 and medically-attended AEs from D8 to D28 post-vaccination and followed all events until resolved.",
            "startOffset": 25749,
            "title": "Safety assessments"
        },
        {
            "endOffset": 24644,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective of the study evaluated the persistence of antibody response in groups ACWY-4 and ACWY-2, measured by percentages of children with hSBA titers \u22658 against serogroups A, C, W and Y. Secondary objectives included assessing functional antibody levels in vaccine-na\u00efve children aged 40 and 60 months, and comparing antibody responses 1 month after a single dose of MenACWY-CRM in groups ACWY-4 and ACWY-2 with those in group Na\u00efve-60M.",
            "startOffset": 24193,
            "title": "Study objectives"
        },
        {
            "endOffset": 41780,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, this study was limited by the open design and the absence of a control group.",
            "startOffset": 41694,
            "title": "Discussion"
        },
        {
            "endOffset": 35997,
            "parents": [],
            "secId": "s0065",
            "sentence": "We demonstrated that, at 4 years post-immunization, antibody levels measured by both assays were overall higher in children vaccinated with MenACWY-CRM during the first 2 years of life than in na\u00efve children of similar age, although some exceptions were noted for hSBA results for serogroup A.",
            "startOffset": 35704,
            "title": "Discussion"
        },
        {
            "endOffset": 40871,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 40870,
                    "startOffset": 40866
                }
            },
            "secId": "s0065",
            "sentence": "Against serogroup A, however, hSBA and rSBA responses wane differently, with hSBA titers usually dropping rapidly post-vaccination, while rSBA titers remain high [16].",
            "startOffset": 40704,
            "title": "Discussion"
        },
        {
            "endOffset": 19813,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 19812,
                    "startOffset": 19809
                }
            },
            "secId": "s0005",
            "sentence": "The incidence of IMD varies by age group, peaking in infants and in adolescents and young adults [5].",
            "startOffset": 19712,
            "title": "Introduction"
        },
        {
            "endOffset": 22891,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase 3b, open-label study (NCT01148017) performed between July 2010 and April 2013 in 19 centers in the US.",
            "startOffset": 22772,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35519,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Although a few combinations of serogroup, age, timepoint of vaccination and number of doses had a statistically significant correlation coefficient between rSBA and hSBA titers, we could not identify an overall correlation between the 2 assays (Table S3).",
            "startOffset": 35264,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 21635,
            "parents": [],
            "secId": "s0005",
            "sentence": "We also evaluated a potential correlation between human and rabbit complement serum bactericidal assay (hSBA/rSBA) titers, based on serological data generated in the current study and 2 other trials assessing long-term persistence following MenACWY-CRM immunization in infants, children and adolescents (Fig. 1).",
            "startOffset": 21323,
            "title": "Introduction"
        },
        {
            "endOffset": 42890,
            "parents": [],
            "secId": "s0070",
            "sentence": "Vaccination of infants and toddlers with MenACWY-CRM resulted in moderate antibody persistence against serogroups C, W and Y at 60 months of age.",
            "startOffset": 42745,
            "title": "Conclusions"
        },
        {
            "endOffset": 19711,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 19710,
                    "startOffset": 19705
                },
                "b0010": {
                    "endOffset": 19710,
                    "startOffset": 19705
                },
                "b0015": {
                    "endOffset": 19710,
                    "startOffset": 19705
                },
                "b0020": {
                    "endOffset": 19710,
                    "startOffset": 19705
                }
            },
            "secId": "s0005",
            "sentence": "Invasive meningococcal disease (IMD) is a life-threatening condition, which has a case-fatality rate of 10%, and causes permanent sequelae in 10\u201320% of survivors [1\u20134].",
            "startOffset": 19543,
            "title": "Introduction"
        },
        {
            "endOffset": 36657,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 36656,
                    "startOffset": 36649
                },
                "b0115": {
                    "endOffset": 36627,
                    "startOffset": 36620
                },
                "b0120": {
                    "endOffset": 36627,
                    "startOffset": 36620
                },
                "b0125": {
                    "endOffset": 36627,
                    "startOffset": 36620
                },
                "b0130": {
                    "endOffset": 36656,
                    "startOffset": 36649
                }
            },
            "secId": "s0065",
            "sentence": "Our observation is further supported by trials in 2\u201318-year-olds which showed less pronounced waning of antibody titers over time in individuals receiving vaccination in adolescence [23\u201325] than at younger ages [16,26].",
            "startOffset": 36438,
            "title": "Discussion"
        },
        {
            "endOffset": 38670,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although we observed higher rSBA GMTs than hSBA GMTs for all age groups and serogroups, the percentages of children with hSBA titers \u22654 and rSBA titers \u22658 were comparable.",
            "startOffset": 38499,
            "title": "Discussion"
        },
        {
            "endOffset": 21794,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase 3b, open-label study (NCT01148017) performed between July 2010 and April 2013 in 19 centers in the US.",
            "startOffset": 21675,
            "title": "Study design and participants"
        },
        {
            "endOffset": 43316,
            "parents": [],
            "secId": "s0070",
            "sentence": "Regardless of prior vaccination status, a dose of MenACWY-CRM at 60 months of age was immunogenic and well-tolerated in all children.",
            "startOffset": 43183,
            "title": "Conclusions"
        },
        {
            "endOffset": 34539,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The percentages of individuals with rSBA titers \u22658 and antibody GMTs were higher in groups previously vaccinated with MenACWY-CRM than in the corresponding na\u00efve cohorts, for all age categories and serogroups (including A), except for serogroup C for children 7\u201310 years of age receiving either 1 or 2 doses of MenACWY-CRM 5 years earlier (Table S2).",
            "startOffset": 34189,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        },
        {
            "endOffset": 23250,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 23249,
                    "startOffset": 23245
                }
            },
            "secId": "s0015",
            "sentence": "We evaluated the persistence of antibody titers in 2 groups of healthy 40- and 60-month-olds previously vaccinated with MenACWY-CRM, primed either according to a 3 + 1 schedule at 2, 4, 6, and 12/13 months of age (group ACWY-4) or according to a 2-dose (at 12/13 months and 15 months of age) or single-dose schedule (at 18 months of age) (group ACWY-2) [17].",
            "startOffset": 22892,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40222,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 40221,
                    "startOffset": 40217
                }
            },
            "secId": "s0065",
            "sentence": "Consistent with this, another study showed that the majority of unvaccinated individuals with rSBA titers \u22658 also had hSBA titers \u22654 and that rSBA titers \u22648 indicated susceptibility to IMD [34].",
            "startOffset": 40028,
            "title": "Discussion"
        },
        {
            "endOffset": 29383,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "For serogroup A, these values were similar between the ACWY-4 and Na\u00efve-40M groups (as shown by overlapping 95% CIs), and lower than in group ACWY-2.",
            "startOffset": 29234,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "For children who received a MenACWY-CRM dose at 40 months of age, investigators also collected SAEs and medically attended AEs (graded by severity and relatedness to vaccination) reported within 28 days post-vaccination.",
            "startOffset": 26125,
            "title": "Safety assessments"
        },
        {
            "endOffset": 30888,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "For serogroup A, at both pre-vaccination timepoints, rSBA GMTs were higher in the previously primed children than in the na\u00efve group (Table 3).",
            "startOffset": 30745,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32781,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Among vaccinated 40-month-olds (Na\u00efve-40M group), we recorded 5 medically-attended AEs in 3/11 (27%) children: acute otitis media, upper respiratory tract infection, viral pharyngitis, arthralgia and ingrown nail; none were related to vaccination.",
            "startOffset": 32534,
            "title": "Safety"
        },
        {
            "endOffset": 25624,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Investigators recorded solicited local and systemic adverse events (AEs) occurring within 30 min post-vaccination for all children receiving a MenACWY-CRM dose at 60 months of age.",
            "startOffset": 25444,
            "title": "Safety assessments"
        },
        {
            "endOffset": 26674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming a drop-out rate of 20%, this would result in a sample size of 160 participants in the according-to-protocol (ATP) cohorts, including children with evaluable serum samples at each timepoint and no major protocol deviations.",
            "startOffset": 26443,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30554,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 40 months of age, the percentages with rSBA titers \u22658 and rSBA GMTs were higher in primed than in age-matched na\u00efve children for all serogroups except serogroup C.",
            "startOffset": 30388,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 33163,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The subsets of children with rSBA assessments in each of the 3 studies included in the exploratory analyses had comparable demographic characteristics at each timepoint (Table S1).",
            "startOffset": 32983,
            "title": "Correlation between hSBA and rSBA results for antibody persistence"
        }
    ],
    "docId": "S0264410X19308539",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "Nicola.Klein@kp.org",
                "first": "Nicola P.",
                "initial": "N.P.",
                "last": "Klein"
            },
            {
                "email": null,
                "first": "Stan L.",
                "initial": "S.L.",
                "last": "Block"
            },
            {
                "email": "bessink@mcrmed.com",
                "first": "Brandon",
                "initial": "B.",
                "last": "Essink"
            },
            {
                "email": "silvia.x.barbi@gsk.com",
                "first": "Silvia",
                "initial": "S.",
                "last": "Barbi"
            },
            {
                "email": null,
                "first": "Igor",
                "initial": "I.",
                "last": "Smolenov"
            },
            {
                "email": "pavitra.x.keshavan@gsk.com",
                "first": "Pavitra",
                "initial": "P.",
                "last": "Keshavan"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.06.076",
        "firstpage": "4460",
        "issn": "0264410X",
        "keywords": [
            "Booster",
            "MenACWY-CRM",
            "Meningococcal",
            "Persistence",
            "hSBA",
            "rSBA"
        ],
        "lastpage": "4467",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods"
    }
}